Tarsus Pharmaceuticals is a biopharmaceutical company focused on the development of therapeutic candidates to address large market opportunities initially in ophthalmic conditions. Its lead product candidate, TP-03, is a therapeutic in Phase 2b/3 that is developed for the treatment of blepharitis caused by the infestation of Demodex mites, which is referred to as Demodex blepharitis.